These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20521170)

  • 1. Cystic fibrosis newborn screening: using experience to optimize the screening algorithm.
    Hale JE; Parad RB; Dorkin HL; Gerstle R; Lapey A; O'Sullivan BP; Spencer T; Yee W; Comeau AM
    J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S255-61. PubMed ID: 20521170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
    Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF
    J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
    Parad RB; Comeau AM
    J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
    Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
    Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
    Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
    J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
    Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
    J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
    Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
    J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis newborn screening: the importance of bloodspot sample quality.
    Doull I; Course CW; Hanks RE; Southern KW; Forton JT; Thia LP; Moat SJ
    Arch Dis Child; 2021 Mar; 106(3):253-257. PubMed ID: 32859613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
    Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
    J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey of newborn screening for cystic fibrosis in Europe.
    Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
    J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for cystic fibrosis in New York State: considerations for algorithm improvements.
    Kay DM; Maloney B; Hamel R; Pearce M; DeMartino L; McMahon R; McGrath E; Krein L; Vogel B; Saavedra-Matiz CA; Caggana M; Tavakoli NP
    Eur J Pediatr; 2016 Feb; 175(2):181-93. PubMed ID: 26293390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of specificity and sensitivity of IRT/IRT protocol in the cystic fibrosis newborn screening program: 6-year experience of three tertiary centers.
    Ramasli Gursoy T; Asfuroglu P; Sismanlar Eyuboglu T; Aslan AT; Yilmaz AI; Unal G; Kibar BS; Pekcan S; Hangul M; Kose M; Budakoglu II; Acican D
    Eur J Pediatr; 2023 Mar; 182(3):1067-1076. PubMed ID: 36565324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
    Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
    J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA.
    Krulišová V; Balaščaková M; Skalická V; Piskáčková T; Holubová A; Paděrová J; Křenková P; Dvořáková L; Zemková D; Kračmar P; Chovancová B; Vávrová V; Stambergová A; Votava F; Macek M
    Eur J Pediatr; 2012 Aug; 171(8):1223-9. PubMed ID: 22581207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening.
    Kay DM; Langfelder-Schwind E; DeCelie-Germana J; Sharp JK; Maloney B; Tavakoli NP; Saavedra-Matiz CA; Krein LM; Caggana M; Kier C;
    Pediatr Pulmonol; 2015 Aug; 50(8):771-80. PubMed ID: 26098992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.
    Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M
    Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosing cystic fibrosis in newborn screening in Poland - 15 years of experience.
    Sands D; Zybert K; Mierzejewska E; Ołtarzewski M
    Dev Period Med; 2015; 19(1):16-24. PubMed ID: 26003066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
    Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
    Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.
    Castellani C; Picci L; Scarpa M; Dechecchi MC; Zanolla L; Assael BM; Zacchello F
    Am J Med Genet A; 2005 Jun; 135(2):142-4. PubMed ID: 15832355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome.
    Ren CL; Desai H; Platt M; Dixon M
    Pediatr Pulmonol; 2011 Nov; 46(11):1079-84. PubMed ID: 21538969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.